---

---

•	better reflects how management and the analyst community view the business as a single operating unit,

•	enhances investor understanding of our company by enabling them to view the business as a whole and in the same manner as management,

•	is more efficient for our company and results in savings in time, effort and expense, and

•	is more efficient for investors by reducing duplicative disclosure and providing a single document for their review.

•	consolidated financial statements,

•	the following notes to the consolidated financial statements:

•	Equity / Partners’ Capital,

•	Debt, and

---

•	Earnings Per Share / Unit,

•	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities, and

•	Liquidity and Capital Resources in Management’s Discussion and Analysis of Financial Condition and Results of Operations.

---

---

•	adverse economic or real estate developments in the life science industry or in our target markets, including the inability of our tenants to obtain funding to run their businesses,

•	our dependence on significant tenants,

•	our failure to obtain necessary outside financing on favorable terms or at all, including the continued availability of our unsecured line of credit,

•	general economic conditions, including downturns in the foreign, domestic and local economies,

•	changes in interest rates and foreign currency exchange rates,

•	volatility in financial and securities markets,

•	defaults on or non-renewal of leases by tenants,

•	our inability to compete effectively,

•	increased operating costs,

•	our inability to successfully complete real estate acquisitions, developments and dispositions,

•	risks and uncertainties affecting property development and construction,

•	risks associated with tax credits, grants and other subsidies to fund development activities,

•	our failure to effectively manage our growth and expansion into new markets or to successfully operate acquired properties and companies,

•	our ownership of properties outside of the United States that subject us to different and potentially greater risks than those associated with our domestic operations,

•	risks associated with our investments in loans, including borrower defaults and potential principal losses,

•	reductions in asset valuations and related impairment charges,

•	the loss of services of one or more of our executive officers,

•	BioMed Realty Trust, Inc.’s failure to qualify or continue to qualify as a REIT,

---

•	our failure to maintain our investment grade corporate credit ratings or a downgrade in our investment grade corporate credit ratings from one or more of the rating agencies,

•	government approvals, actions and initiatives, including the need for compliance with environmental requirements,

•	the effects of earthquakes and other natural disasters,

•	lack of or insufficient amounts of insurance,

•	risks associated with security breaches and other disruptions to our information technology networks and related systems, and

•	changes in real estate, zoning and other laws and increases in real property tax rates.

---

---

(1)	Rentable square feet at time of acquisition.

(2)	Investment includes a noncontrolling interest of $5.0 million, an assumed construction loan of $21.7 million and approximately $102.3 million in estimated completion costs at time of acquisition.

(3)	Investment includes a noncontrolling interest of $5.0 million and an assumed mortgage note payable of $46.3 million.

(4)	Investment includes £12.0 million to be paid upon completion of the building.

(5)	Investment includes approximately $47.8 million in estimated completion costs, net of tax credits funding, at time of acquisition.

(6)	Excludes approximately 2.3 million square feet of estimated potential development resulting from a 99-year ground lease entered into with Drexel University for approximately $18.2 million during 2014.

•	Signed a 15-year lease with Illumina on a new 360,000 square foot life science campus consisting of two buildings in Foster City, California, with an option for Illumina to expand the campus with the development of a third building providing at least an additional 160,000 square feet, which would bring the campus to a total of at least 520,000 square feet.

•	Initiated a new, fully-leased build-to-suit investment to comprise approximately 42,400 square feet of laboratory and office space in the Cambridge Science Park in Cambridge, United Kingdom. The property is 100% pre-leased to Takeda Pharmaceutical Company Limited for 16 years.

•	Commenced construction of a 122,700 square foot laboratory and office building at 500 Fairview Avenue in Seattle, Washington.

•	Entered into a 99-year ground lease on a 10-acre site in Philadelphia for future development through a collaboration between Drexel University and Wexford Science & Technology, LLC and related entities, or Wexford.

•	Completed construction of the 3737 Science Center life science building on the Science Center campus in Philadelphia, Pennsylvania, a 334,000 square foot laboratory and office building developed through a joint venture between the University City Science Center and Wexford.

•	Completed a public offering of $400.0 million of unsecured 2.625% Senior Notes due 2019, or the Notes due 2019, issued at 99.408% of the principal amount to yield 2.752% to maturity.

---

•

Issued 4,955,377 shares of BioMed Realty Trust, Inc.'s common stock in exchange for approximately $84.3 million in aggregate principal amount of the Exchangeable Senior Notes due 2030, or the Exchangeable Senior Notes, at the request of the holders that exercised their exchange right. Subsequent to December 31, 2014, we issued 5,764,026 shares of BioMed Realty Trust, Inc.'s common stock in exchange for the remaining $95.7 million in aggregate principal amount of the Exchangeable Senior Notes, at the request of the remaining holders.

•	Repaid in full the $333.4 million principal amount outstanding on our mortgage loan secured by the Center for Life Science | Boston, which bore interest at 7.75% per annum.

•	Ended the fourth quarter with a debt to total gross assets ratio of 38.1%, with approximately $816.0 million of capacity on our unsecured line of credit.

•	Janice L. Sears, an experienced executive, investment banker and commercial real estate expert, joined our board of directors in April 2014.

•	David Hsiao was promoted to Vice President, Information Technology in February 2014.

•	negotiating leases with contractual rental rate increases in order to provide predictable and consistent earnings growth,

•	creating strong relationships with our tenants to enable us to identify and capitalize on opportunities to renew or extend existing leases or to provide expansion space,

•	redeveloping currently owned non-laboratory space into higher yielding laboratory facilities, and

•	developing new laboratory and office space on land we have acquired for development.

---

•	acquiring, subject to our rigorous underwriting standards, well-located properties leased to high-quality life science tenants with attractive in-place yields and long-term growth potential,

•	investing in properties with leasing opportunities, capitalizing on our industry relationships to enter into new leases, and

•	investing in redevelopment and development projects, capitalizing on our development platform that we believe will serve as an additional catalyst for future growth.

•	the aging of the U.S. population resulting from the transition of baby boomers to senior citizens, which has increased the demand for new drugs and health care treatment alternatives to extend, improve and enhance their quality of life, and

•	escalating health care costs, which drive the demand for better drugs, less expensive treatments and more services in an attempt to manage such costs.

---

---

•	our expertise in understanding the real estate needs of life science industry tenants,

•	our ability to identify, acquire and develop properties with generic laboratory infrastructure that appeal to a wide range of life science industry tenants, and

•	our expertise in identifying and evaluating life science industry tenants.

---

•

Our tenants require significant outlays of funds for the research and development and clinical testing of their products and technologies and many of them have a history of recurring losses. The economic environment in recent years has significantly impacted the ability of these companies to access the capital markets and venture capital funding. In addition, state and federal government and university budgets have been negatively impacted by the recent economic environment and, as a result certain programs, including grants related to biotechnology research and development, may be at risk of being eliminated or cut back significantly. If private investors, the government, universities, public markets or other sources of funding are unavailable to support such development, a tenant’s business may fail.

•

The research and development, clinical testing, manufacture and marketing of some of our tenants’ products require federal, state and foreign regulatory approvals. The approval process is typically long, expensive and uncertain. Even if our tenants have sufficient funds to seek approvals, one or all of their products may fail to obtain the required regulatory approvals on a timely basis or at all. Furthermore, our tenants may only have a small number of products under development. If one product fails to receive the required approvals at any stage of development, it could significantly adversely affect our tenant’s entire business and its ability to pay rent.

•	Our tenants may be unable to adequately protect their intellectual property under patent, copyright or trade secret laws. Failure to do so could jeopardize their ability to profit from their efforts and to protect their products from competition.

---

•	Collaborative relationships with other life science entities may be crucial to the development, manufacturing, distribution or marketing of our tenants’ products. If these other entities fail to fulfill their obligations under these collaborative arrangements, our tenants’ businesses will suffer.

•

Legislation to reform the U.S. healthcare system, including regulations and legislation relating to the Affordable Care Act, may include government intervention in product pricing and other changes that adversely affect reimbursement for our tenants’ marketable products. In addition, sales of many of our tenants’ marketable products are dependent, in large part, on the availability and extent of reimbursement from government health administration authorities, private health insurers and other organizations. Changes in government regulations, price controls or third-party payors’ reimbursement policies may reduce reimbursement for our tenants’ marketable products and adversely impact our tenants’ businesses.

•	we may spend more time or money than we budget to improve or renovate acquired properties or to develop new properties,

•	we may be unable to quickly and efficiently integrate new properties, particularly if we acquire portfolios of properties, into our existing operations,

•	market and economic conditions may result in higher than expected vacancy rates and lower than expected rental rates,

•	we may face higher operating costs than we anticipated for properties that we acquire, develop or renovate, including insurance premiums, utilities, real estate taxes and costs of complying with changes in governmental regulations,

•	we may face higher requirements for capital improvements than we anticipated for properties that we acquire, develop or renovate, particularly in older structures,

•	we may fail to retain tenants that have pre-leased our properties under development if we do not complete the construction of these properties in a timely manner or to the tenants’ specifications,

•	we have a limited history in conducting ground-up construction activities,

•	if we develop properties, we may encounter delays or refusals in obtaining all necessary zoning, land use, building, occupancy and other required governmental permits and authorizations,

•	acquired and developed properties may have defects we do not discover through our inspection processes, including latent defects that may not reveal themselves until many years after we put a property in service, and

•	we may acquire land, properties or entities owning properties, which are subject to liabilities and for which, in the case of unknown liabilities, we may have limited or no recourse.

---

•	reinforced concrete floors,

•	upgraded roof structures for greater load capacity,

•	increased floor-to-ceiling clear heights,

•	heavy-duty HVAC systems,

•	enhanced environmental control technology,

•	significantly upgraded electrical, gas and plumbing infrastructure, and

•	laboratory benchwork.

---

•	local oversupply, increased competition or reduced demand for life science office and laboratory space,

---

•	inability to collect rent from tenants,

•	vacancies or our inability to rent space on favorable terms,

•	potential changes in U.S. accounting standards regarding leases making leasing of our properties less attractive to tenants,

•	increased operating costs, including insurance premiums, utilities and real estate taxes,

•	the ongoing need for capital improvements, particularly in older structures,

•	unanticipated delays in the completion of our development or redevelopment projects,

•	costs of complying with changes in governmental regulations, including usage, zoning, environmental and tax laws,

•	the relative illiquidity of real estate investments,

•	changing submarket demographics, and

•	civil unrest, acts of war and natural disasters, including earthquakes, floods and fires, which may result in uninsured and underinsured losses.

•	future periods of economic slowdown or recession,

•	rising interest rates,

•	declining demand for real estate, or

•	the public perception that any of these events may occur.

---

---

•	the owner’s knowledge of the contamination,

•	the timing of the contamination,

•	the cause of the contamination, or

•	the party responsible for the contamination.

•	may require the removal or upgrade of underground storage tanks,

---

•	regulate the discharge of storm water, wastewater and other pollutants,

•	regulate air pollutant emissions,

•	regulate hazardous materials generation, management and disposal, and

•	regulate workplace health and safety.

---

•	We may not be able to refinance or extend our existing debt. If we cannot repay, refinance or extend our debt at maturity, in addition to our failure to repay our debt, we may be unable to make distributions to BioMed Realty, L.P.’s unit holders or BioMed Realty Trust, Inc.’s stockholders at expected levels or at all.

•	Even if we are able to refinance or extend our existing debt, the terms of any refinancing or extension may not be as favorable as the terms of our existing debt. If the refinancing involves a higher interest rate, it could adversely affect our cash flow and ability to make distributions to unit holders and stockholders.

•	Required payments of principal and interest may be greater than our cash flow from operations.

•	We may be forced to dispose of one or more of our properties, possibly on disadvantageous terms, to make payments on our debt.

•	One or more lenders under our $900.0 million unsecured line of credit could refuse to fund their financing commitment to us or could fail, and we may not be able to replace the financing commitment of any such lenders on favorable terms, or at all.

•	If we default on our debt obligations, the lenders or mortgagees may foreclose on our properties that secure those loans. Further, if we default under a mortgage loan, we will automatically be in default on any other loan that has cross-default provisions, and we may lose the properties securing all of these loans.

•

A foreclosure on one of our properties will be treated as a sale of the property for a purchase price equal to the outstanding balance of the secured debt. If the outstanding balance of the secured debt exceeds our tax basis in the property, we would recognize taxable income on foreclosure without realizing any accompanying cash proceeds to pay the tax (or to make distributions based on REIT taxable income).

---

---

•	general market conditions

•	the market’s perception of our growth potential,

•	with respect to acquisition financing, the market’s perception of the value of the properties to be acquired,

•	our current debt levels,

•	our current and expected future earnings,

•	our cash flow and cash distributions, and

•	the market price of BioMed Realty Trust, Inc.’s common stock.

•	Available interest rate hedging may not correspond directly with the interest rate risk for which we seek protection.

•	The duration or the amount of the hedge may not match the duration or amount of the related liability.

•	The party owing money in the hedging transaction may default on its obligation to pay.

•	The credit quality of the party owing money on the hedge may be downgraded to such an extent that it impairs our ability to sell or assign our side of the hedging transaction.

•	The value of derivatives used for hedging may be adjusted from time to time in accordance with accounting rules to reflect changes in fair-value. Downward adjustments, or “mark-to-market losses,” would reduce our stockholders’ equity.

---

•	non-compliance with applicable laws, regulations and contractual provisions could result in projected benefits not being realized, and, with regard to historic tax credits and new market tax credits, require a refund or reduction of capital contributions from the investor that is a party to that transaction,

•	counterparty credit risks and funding risks, including, for example, the reliance in part on increasing real estate values to repay investors in tax increment financing transactions,

•	changes in government rules that eliminate, reduce or otherwise adversely affect our ability to qualify for the benefits of these arrangements, and

•	potential increases in federal income taxes on taxable income at regular corporate tax rates for certain arrangements where we are required to utilize a taxable REIT subsidiary.

---

•

“business combination” provisions that, subject to limitations, prohibit certain business combinations between us and an “interested stockholder” or an affiliate of an interested stockholder for certain periods. An “interested stockholder” is generally any person who beneficially owns 10% or more of the voting power of BioMed Realty Trust, Inc.’s outstanding voting shares or an affiliate or associate of ours who, at any time within the two-year period immediately prior to the date in question, was the beneficial owner of 10% or more of the voting power of BioMed Realty Trust, Inc.’s then outstanding stock. A person is not an interested stockholder under the statute if the board of directors approved in advance the transaction by which he otherwise would have become an interested stockholder. Business combinations with an interested stockholder are prohibited for five years after the most recent date on which the stockholder becomes an interested stockholder. After that period, the MGCL imposes two super-majority voting requirements on such business combinations, and

•

“control share” provisions that provide that holders of “control shares” of BioMed Realty Trust, Inc. acquired in a “control share acquisition” have no voting rights except to the extent approved by a vote of two-thirds of the votes entitled to be cast on the matter (excluding interested shares). “Control shares” are voting shares that, when aggregated with all other shares owned by the stockholder or in respect of which the stockholder is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), entitle the stockholder to exercise one of three increasing ranges of voting power in electing directors. A “control share acquisition” is the direct or indirect acquisition of ownership or control of “control shares.”

•	might become bankrupt or fail to fund their share of required capital contributions,

•	may have economic or other business interests or goals that are inconsistent with our business interests or goals, and

•	may be in a position to take actions contrary to our policies or objectives.

---

•	we structure a joint venture or conduct business in a manner that is deemed to be a general partnership with a third party, in which case we could be liable for the acts of that third party,

•	third-party managers incur debt or other liabilities on behalf of a joint venture which the joint venture is unable to pay, and the joint venture agreement provides for capital calls, in which case we could be liable to make contributions as set forth in any such joint venture agreement, or

•	we agree to cross-default provisions or to cross-collateralize our properties with the properties in a joint venture, in which case we could face liability if there is a default relating to those properties in the joint venture or the obligations relating to those properties.

•	we would not be allowed to deduct distributions to stockholders in computing our taxable income and would be subject to federal income tax at regular corporate rates,

•	we could also be subject to the federal alternative minimum tax and possibly increased state and local taxes, and

•	unless we are entitled to relief under applicable statutory provisions, BioMed Realty Trust, Inc. could not elect to be taxed as a REIT for four taxable years following the year in which BioMed Realty Trust, Inc. was disqualified.

---

•	differences in timing between the actual receipt of cash and inclusion of income for federal income tax purposes,

•	the effect of non-deductible capital expenditures,

•	the creation of reserves, or

•	required debt or amortization payments.

•	actual or anticipated variations in our quarterly operating results or distributions,

•	changes in our funds from operations or earnings estimates,

•	publication of research reports about us or the real estate industry,

•	increases in market interest rates that lead purchasers of BioMed Realty Trust, Inc.’s shares to demand a higher yield,

•	changes in market valuations of similar companies,

•	adverse market reaction to any additional debt we incur or acquisitions we make in the future,

•	additions or departures of key management personnel,

•	actions by institutional stockholders,

•	speculation in the press or investment community,

•	the realization of any of the other risk factors presented in this report, and

•	general market and economic conditions.

---

•	cash available for distribution,

•	operating results,

•	our financial condition, especially in relation to our anticipated future capital needs,

•	then current expansion plans,

•	the distribution requirements for REITs under the Code, and

•	other factors our board deems relevant.

•	the exchange of operating partnership units, or LTIP units,

•	additional grants of LTIP units, restricted stock or other securities to our directors, executive officers and other employees under our incentive award plan,

•	issuances of preferred stock with liquidation or distribution preferences, and

•	other issuances of BioMed Realty Trust, Inc.’s common stock.

---

•	our limited knowledge of and relationships with sellers, tenants, contractors, suppliers or other parties in these markets,

•	challenges in managing and integrating international operations, development and redevelopment, including difficulty in hiring qualified management, sales and construction personnel and service providers in a timely fashion,

•	changes in foreign political, regulatory and economic conditions, including regionally, nationally and locally,

•	challenges of complying with a wide variety of foreign laws and regulations, including those relating to real estate, corporate governance, operations, taxes, employment and legal proceedings,

•	establishing effective controls and procedures to regulate the operations of new offices and to monitor compliance with U.S. laws and regulations such as the Foreign Corrupt Practices Act and similar foreign laws and regulations,

•	adverse effects of changes in exchange rates for foreign currencies,

•	challenges with respect to the repatriation of foreign earnings,

•	differences in lending practices, and

•	differences in languages, cultures and time zones.

---

•	A loan may become non-performing or sub-performing for a variety of reasons outside of our control, including, without limitation, because the underlying property is too highly leveraged, the borrower falls upon financial distress or the property fails to perform as expected, resulting in the borrower being unable to meet its debt service obligations to us.

•	A non-performing or sub-performing loan may require a substantial amount of workout negotiations and/or restructuring, which may divert the attention of our management from other activities and entail, among other things, a substantial reduction in the interest rate, capitalization of interest payments and a substantial write-down of the principal of the loan.

•	If we find it necessary or desirable to foreclose on one or more loans we acquire, the foreclosure process may be lengthy and expensive, with an uncertain outcome, and the underlying property’s value may deteriorate as a result.

•

As was the case with our investment in the Construction Loan, we may co-invest in mortgage loans with other investors. As a result, we may lack sole decision-making authority, rely on co-investors’ financial condition and/or have disputes between us and other co-investors. In addition, such co-investors may become bankrupt or fail to fund their share of required capital contributions, have economic or other business interests or goals that are inconsistent with our business interests or goals, or take actions contrary to our policies or objectives.

---

(1)	Calculated based on gross book value for each asset multiplied by the percentage leased.

---

---

---

(1)	The property was under active new construction at December 31, 2014.

(2)	We own an 87.5% membership interest in the limited liability company that owns this property.

(3)	We own a 60% membership interest in the limited liability company that owns this property.

(4)	We own a 68% membership interest in the limited liability company that owns this property.

(5)	We own a 93% membership interest in the limited liability company that owns this property. The property is located in New Haven, Connecticut.

(6)	Located in St. Louis, Missouri.

(7)	Located in Norfolk, Virginia.

(8)	Located in Longmont, Colorado.

(9)	Located in Miami, Florida.

(10)	Located in Chicago, Illinois.

(11)	Located in Boulder, Colorado.

(12)	We are a member of the limited liability companies that own a portfolio of properties in Cambridge, Massachusetts, which entitles us to approximately 20% of the operating cash flows.

(13)	We own the general partnership interest in the limited partnership that owns the McKellar Court property, which entitles us to 75% of the extraordinary cash flows after repayment of the partners’ capital contributions and 22% of the operating cash flows. The property is located in San Diego, California.

---

(1)	Based on current annualized base rent. Current annualized base rent is the monthly contractual rent as of the current period end, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.

(2)	On April 3, 2013, we entered into a build-to-suit agreement to construct two new buildings pre-leased to Regeneron for a 15-year term totaling approximately 297,000 square feet at Landmark at Eastview. 2,833 square feet will expire in July 2015, 7,568 square feet in January 2017, 82,124 square feet in January 2019, 232,049 square feet in July 2024 and 678,792 square feet in July 2029.

(3)	81,204 square feet are leased to a subsidiary of Vertex Pharmaceuticals Incorporated. 292,758 square feet expire January 2016, 20,608 square feet expire May 2017, 290,716 square feet expire May 2018, and 81,204 square feet expire January 2019.

(4)	The tenant is Human Genome Sciences (HGS), a wholly-owned subsidiary of GlaxoSmithKline plc (GSK). GSK has executed a payment guarantee with respect to rental payments due under our leases with HGS.

(5)	343,000 square feet expire August 2018 and 75,003 square feet expire October 2018.

(6)	28,057 square feet expire July 2017, 193,136 square feet expire November 2024, 200,000 square feet expire July 2032 and 160,000 square feet expire July 2033.

(7)	This tenant guarantees rent on 49,866 square feet leased at the Center for Life Science│Boston.

(8)	3,134 square feet expire January 2018 and 410,411 square feet expire January 2025.

(9)	242,000 square feet expire January 2028, 119,200 square feet expire April 2029 and 167,947 square feet expire July 2031. Wake Forest University is the sole member of the tenant, Wake Forest University Health Services.

---

(10)	24,437 square feet expire July 2015, 21,576 square feet expire December 2015, 39,505 square feet expire January 2021 and 160,290 square feet expire in December 2021.

(11)	149,984 square feet expire July 2016 and 78,023 square feet expire August 2016.

(12)	9,330 square feet expire July 2015, 4,680 square feet expire in August 2015, 8,478 square feet expire June 2016, 10,578 square feet expire March 2018, 15,436 square feet expire September 2020, 20,143 square feet expire March 2022, 19,912 square feet expire June 2025, 4,796 square feet expire November 2025, 208,777 square feet expire May 2032 and 95,272 square feet expire March 2036.

(13)	176,000 square feet expire July 2031 and 28,704 square feet expire January 2032.

(14)	30,167 square feet expire April 2024 and 194,108 square feet expire June 2025.

(15)	Without regard to any early lease terminations and/ or renewal options.

---

(1)	Excludes a special dividend of $0.30 per share of common stock declared during the fourth quarter 2014, reflecting a return to stockholders of a portion of the proceeds from the sale of our 9911 Belward Campus Drive property.

(1)	Excludes a special distribution of $0.30 per unit declared during the fourth quarter 2014, reflecting a return to unit holders of a portion of the proceeds from the sale of our 9911 Belward Campus Drive property.

---

---

(1)	Excludes a special dividend of $0.30 per share of common stock declared during the year ended December 31, 2014, reflecting a return to stockholders of a portion of the proceeds from the sale of our 9911 Belward Campus Drive property.

---

(1)	Excludes a special distribution of $0.30 per unit declared during the year ended December 31, 2014, reflecting a return to unit holders of a portion of the proceeds from the sale of our 9911 Belward Campus Drive property.

---

(1)	Calculated based on gross book value for each asset multiplied by the percentage leased.

---

---

•	whether the lease stipulates how and on what a tenant improvement allowance may be spent;

•	whether the tenant or landlord retain legal title to the improvements;

•	the uniqueness of the improvements;

•	the expected economic life of the tenant improvements relative to the length of the lease;

•	the responsible party for construction cost overruns; and

•	who constructs or directs the construction of the improvements.

---

---

---

(1)	Current annualized base rent per leased square foot is the monthly contractual rent per leased square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per leased square foot due at each rent commencement date, multiplied by 12 months.

(2)	Current annualized base rent per leased square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

(3)	Leases on space which is currently occupied and where the leases are expected to commence upon vacancy of the existing tenants.

(4)	Leases on space which, in management’s evaluation, require significant improvements to prepare or condition the premises for its intended purpose or enhance the value of the property. This generally includes capital expenditures for active new construction, active redevelopment or repositioning a property.

(5)	Leases which are not considered by management to be first generation leases.

---

(6)	Leases on space which, prior to the execution, were included in the land bank and are expected to enter our operating portfolio at a future date.

(1)	Includes both rent concessions due to free or discounted rent periods and lease incentives paid to tenants.

(2)	Renewals and extensions were leased at a weighted-average current annualized base rent of $27.53 per square foot, representing an increase of 4.1% over the previously expiring rents on a GAAP basis.

(3)	Includes new leases - second generation forward leases.

(1)	Includes amounts paid for acquiring the property, landlord improvements and tenant improvement allowances, but for active redevelopment properties excludes any amounts accrued, and payroll, interest or operating expenses capitalized, through December 31, 2014.

(2)	Includes construction costs associated with speculative leasing.

(3)	Management’s estimate of the time in which construction will be substantially completed. A project is considered substantially complete and held available for occupancy upon the completion of tenant improvements, but no later than one year from cessation of major construction activity.

(4)	Phase I of the project is comprised of 200,000 square feet and is estimated to be completed in the third quarter of 2017. Phase II comprising 160,000 square feet is estimated to be delivered in the third quarter of 2018.

(5)	The total investment through December 31, 2014 of $3.6 million was fully offset by tax credit funding received during the three months ended December 31, 2014. Estimated Total Investment is net of expected tax credit benefits.

---

(1)	Includes projects that received tax credit funding that offset actual capital expenditures incurred during the year.

(2)

Recurring capital expenditures exclude (a) items associated with the expansion of a building or its improvements, (b) renovations to a building which change the underlying classification of the building, incurred to prepare or condition the premises for its intended purpose (for example, from office to laboratory) or (c) capital improvements that represent an addition to the property rather than the replacement of property, plant or equipment. Includes revenue enhancing and non-revenue enhancing recurring capital expenditures.

(1)	Includes properties engaged in activities related to planning, entitlement, or other preparations for future development.

(2)	Includes improvements on operating properties, including major tenant improvements projects on properties which are not included in active new construction or active redevelopment.

---

(1)	Rentable square feet at time of acquisition.

(2)	Investment includes a noncontrolling interest of $5.0 million, an assumed construction loan of $21.7 million and approximately $102.3 million in estimated completion costs at time of acquisition.

(3)	Investment includes a noncontrolling interest of $5.0 million and an assumed mortgage note payable of $46.3 million.

(4)	Investment includes £12.0 million to be paid upon completion of the building.

(5)	Investment includes approximately $47.9 million in estimated completion costs at time of acquisition, net of expected tax credit benefits.

(6)	Excludes an estimated 2.3 million square feet of land resulting from a 99-year ground lease entered into with Drexel University for approximately $18.2 million during 2014.

---

(1)	Current annualized base rent per square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

(2)

During the years ended December 31, 2014 and 2013, we recorded lease termination revenue of approximately $12.6 million and $42.8 million, respectively. Lease termination revenue for the year ended December 31, 2014 primarily related to the early termination of leases at our 4570 Executive Drive, 50 Hampshire and Granta Park properties. Lease termination revenue for the year ended December 31, 2013 primarily related to the termination of a lease with Elan Corporation at our Science Center at Oyster Point property, for which Elan paid us $46.5 million in 2013. During the year ended December 31, 2014, we also recorded a prepayment fee of approximately $7.5 million, net of deferred loan fees write-offs, related to the investment in our Construction Loan, which was fully repaid in May 2014 prior to maturity. We also recorded $3.9 million and $5.6 million of interest income related to our Construction Loan during the years ended December 31, 2014 and 2013, respectively.

(3)	Adjustments to cash basis exclude adjustments to expenses accrued in rental operations, but include straight line rents, fair-value lease revenue, lease incentive revenue, bad debt expense and other revenue (including lease termination revenue).

(4)	Includes the 9911 Belward Campus Drive property, which was sold on December 9, 2014.

---

•	The acquisition of properties totaling approximately 2.9 million square feet in the year ended December 31, 2013 and operating properties totaling 518,940 square feet in the year ended December 31, 2014 contributed an additional $27.7 million in net operating income for the year ended December 31, 2014 compared to the year ended December 31, 2013.

•	Same property net operating income increased $3.3 million to $352.6 million for the year ended December 31, 2014 compared to $349.3 million for the year ended December 31, 2013. This increase was primarily due to continued leasing success with annualized base rent on renewals and extensions increasing 4.1% over the previously expiring rents on a GAAP basis.

•	The placement of one property that was operating in 2013 into redevelopment in 2014, partially offset by the placement of four properties that were under development in 2013 into service, resulted in a net decrease of $1.9 million in net operating income for the year ended December 31, 2014 compared to the year ended December 31, 2013.

---

---

(1)	Current annualized base rent per square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

(2)

During the years ended December 31, 2013 and 2012, we recorded lease termination revenue of $42.8 million and $3.5 million, respectively. Lease termination revenue for the year ended December 31, 2013 primarily related to the termination of a lease with Elan at our Science Center at Oyster Point property, for which Elan paid us $46.5 million in 2013. Lease termination revenue for the year ended December 31, 2012 related to the termination of a lease with Merck at our 320 Bent Street property, which expired in August 2013 and for which Merck paid us $8.7 million in August 2012. During the year ended December 31, 2013, we also recorded $5.6 million of interest income related to our Construction Loan.

(3)	Adjustments to cash basis exclude adjustments to expenses accrued in rental operations, but include straight line rents, fair-value lease revenue, lease incentive revenue, bad debt expense and other revenue (including lease termination revenue).

---

•	The acquisition of properties totaling approximately 1.0 million square feet in the year ended December 31, 2012 and properties totaling approximately 2.9 million square feet in the year ended December 31, 2013 contributed an additional $42.2 million in net operating income for the year ended December 31, 2013 compared to the year ended December 31, 2012.

•	The placement of three properties that were operating in 2012 into redevelopment in 2013, partially offset by the placement of two properties that were under development in 2012 into service, reduced net operating income by $6.1 million for the year ended December 31, 2013 compared to the year ended December 31, 2012.

•

Same property net operating income increased $50.3 million to $393.7 million for the year ended December 31, 2013 compared to $343.4 million for the year ended December 31, 2012. This increase was primarily due to lease termination revenue and interest income on our Construction Loan. On a GAAP basis, the current annualized base rent per square foot increased from $38.25 at December 31, 2012 to $38.43 at December 31, 2013 due to lease up of previously vacant space at a higher average rent than our total overall portfolio on a per square foot basis.

---

---

---

(1)	Net income attributable to noncontrolling interests in the operating partnership is included in net income available to unit holders of the operating partnership as reflected in the consolidated financial statements of our operating partnership, included elsewhere herein.

(2)	Reflects interest expense adjustment of the Exchangeable Senior Notes based on the “if converted” method. The years ended December 31, 2014, 2013 and 2012 include 5,678,087, 10,405,224 and 10,259,496 shares of common stock, respectively, potentially issuable pursuant to the exchange feature of the Exchangeable Senior Notes based on the “if converted” method.

(3)	The years ended December 31, 2014, 2013 and 2012 include 1,483,015, 1,391,663 and 1,477,304 shares of unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per share.

---

---

(1)	The principal balance represents the U.S. dollar amount based on the exchange rate of $1.56 to £1.00 at December 31, 2014.

---

(1)	Amounts exclude unamortized debt premiums and unamortized debt discounts.

(2)

In August 2012, the Operating Partnership converted approximately $156.4 million of outstanding borrowings of the Term Loan due 2017 into British pounds sterling (“GBP”) equal to £100.0 million, which was designated as a net investment hedge to mitigate the risk of fluctuations in foreign currency exchange rates. $155.7 million of the principal balance represents the U.S. dollar amount based on the exchange rate of $1.56 to £1.00 at December 31, 2014.

---

(3)

Aggregate amount based on the market closing price of the common stock of our Parent Company of $21.54 per share on the last trading day of the quarter. Limited partners who have been issued OP units have the right to require the operating partnership to redeem part or all of their OP units, which right with respect to LTIP units is subject to vesting and the satisfaction of other conditions. We may elect to redeem those OP units in exchange for shares of our Parent Company’s common stock on a one-for-one basis, subject to adjustment. At December 31, 2014, 197,442,432 of the outstanding OP units had been issued to our Parent Company upon receipt of the net proceeds from the issuance of an equal number of shares of our Parent Company’s common stock.

---

(1)	On April 1, 2014, the Operating Partnership repaid in full the mortgage loan secured by the Company's Center for Life Science | Boston property prior to its scheduled maturity date.

(2)	Mortgage notes payable assumed on April 4, 2014 in connection with the acquisition of the related properties.

(1)	Includes $95.7 million in principal amount of the Exchangeable Senior Notes, which subsequent to December 31, 2014, were exchanged for 5,764,026 shares of our Parent Company's common stock, at the request of the holders.

---

(1)	Balance excludes unamortized debt premium.

(2)	Subsequent to December 31, 2014, the entire principal amount of the Exchangeable Senior Notes was exchanged for 5,764,026 shares of our Parent Company's common stock, at the request of the holders.

(3)	Balance excludes unamortized debt discount.

(4)	Interest payments reflect cash payments that are based on the interest rates in effect and debt balances outstanding on December 31, 2014.

---

(1)	Amount represents our proportionate share of the total outstanding indebtedness for each of the unconsolidated partnerships.

(2)	Effective or weighted-average interest rate of the outstanding indebtedness as of December 31, 2014.

(3)

Amount represents our proportionate share of a secured loan, which bears interest at a LIBOR-indexed variable rate with a borrowing capacity of up to $139.0 million. The secured loan was executed by a wholly-owned subsidiary of PREI I LLC in connection with the construction of the 650 East Kendall Street property. In accordance with the loan agreement, Prudential Insurance Corporation of America has guaranteed repayment of the secured loan. We have an option to extend the maturity date of the secured loan to August 13, 2016 after satisfying certain conditions and paying an extension fee.

---

(1)	Principal balance includes only consolidated indebtedness.

(2)	Includes eleven mortgage notes payable secured by certain of our properties (including unamortized premiums), our Exchangeable Senior Notes, our Notes due 2016 (including unamortized debt discount), our Notes due 2019 (including unamortized debt discount), our Notes due 2020 (including unamortized debt discount) and our Notes due 2022 (including unamortized debt discount).

(3)

Includes the hedged portions of our Term Loan due 2017 and Term Loan due 2018, which bear interest at LIBOR-indexed variable interest rates, plus a credit spread. On August 2, 2012, we converted approximately $156.4 million of outstanding borrowings of the Term Loan due 2017 into GBP equal to £100.0 million. The principal balance represents the U.S. dollar amount based on the exchange rate of $1.56 to £1.00 at December 31, 2014. The stated effective rate for the variable interest hedged debt includes the impact of our interest rate swap agreements. We have entered into four U.S. dollar interest rate swaps, which are intended to have the effect of initially fixing the interest rate on $200.0 million of the outstanding amount under our Term Loan due 2017 at a weighted-average interest rate of approximately 2.39% for the remaining term of the Term Loan due 2017 (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings. We have entered into two GBP interest rate swaps, which are intended to have the effect of initially fixing the interest rate on £100.0 million of the outstanding amount under our Term Loan due 2017 at approximately 2.14% for the remaining term of the Term Loan due 2017 (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings. On September 25, 2013, we entered into three U.S. dollar interest rate swaps, which are intended to have the effect of initially fixing the interest rate on $200.0 million of the outstanding amount under our Term Loan due 2018 at a weighted-average interest rate of approximately 1.90% through October 1, 2016 (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings.

(4)	Includes one variable rate mortgage, the unhedged portions of our Term Loan due 2017 and Term Loan due 2018 and our unsecured line of credit, which bear interest at LIBOR-indexed variable interest rates, plus a credit spread.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

•	whether the lease stipulates how and on what a tenant improvement allowance may be spent;

•	whether the tenant or landlord retain legal title to the improvements;

•	the uniqueness of the improvements;

•	the expected economic life of the tenant improvements relative to the length of the lease;

•	the responsible party for construction cost overruns; and

•	who constructs or directs the construction of the improvements.

---

---

(1)	Determination of fair-value is classified as Level 1 in the fair-value hierarchy based on the use of quoted prices in active markets.

---

---

---

---

---

(1)	Amounts reclassified from loss on derivative instruments are included in interest expense, net in the consolidated statements of operations. See Note 9 for further information.

---

---

(1)	Amounts reclassified from loss on derivative instruments are included in interest expense, net in the consolidated statements of operations. See Note 9 for further information.

---

(1)	On April 1, 2014, the Operating Partnership repaid in full the mortgage loan secured by the Company's Center for Life Science | Boston property prior to its scheduled maturity date.

(2)	Mortgage notes payable assumed on April 4, 2014 in connection with the acquisition of the related properties.

(3)

In August 2012, the Operating Partnership converted approximately $156.4 million of outstanding borrowings into British pounds sterling (“GBP”) equal to £100.0 million, which was designated as a net investment hedge to mitigate the risk of fluctuations in foreign currency exchange rates. The principal balance represents the U.S. dollar amount based on the exchange rates of $1.56 to £1.00 and $1.65 to £1.00 at December 31, 2014 and December 31, 2013, respectively. The effective interest rate includes the impact of interest rate swap agreements (see Note 9 for further discussion of interest rate swap agreements).

(4)	At December 31, 2014, the Operating Partnership had additional borrowing capacity under the unsecured line of credit of up to approximately $816.0 million.

---

---

---

---

---

(1)	Includes $95.7 million in principal payments of the Exchangeable Senior Notes based on the Company's previously announced redemption date of January 30, 2015, which subsequent to December 31, 2014, were exchanged in full for 5,764,026 shares of the Parent Company's common stock at the request of the holders.

---

---

---

---

(1)

PREI I LLC owns two properties in Cambridge, Massachusetts. At December 31, 2014, there were $139.0 million in outstanding borrowings on a secured loan facility held by a wholly-owned subsidiary of PREI I LLC, with a contractual interest rate of 2.21% (including the applicable credit spread) and a maturity date of August 13, 2015 (with an option to extend the maturity date to August 13, 2016 at its discretion after satisfying certain conditions and paying an extension fee).

(2)	The Company’s investment in the McKellar Court partnership (maximum exposure to losses) was approximately $11.8 million at December 31, 2014. The Company’s economic interest in the McKellar Court partnership entitles it to 75% of the extraordinary cash flows after repayment of the partners’ capital contributions and 22% of the operating cash flows.

(1)	The Company acts as the operating member or partner, as applicable, and day-to-day manager for the partnerships. The Company is entitled to receive fees for providing construction and development services (as applicable) and management services to the PREI joint ventures, which are reflected in tenant recoveries and other income in the consolidated statements of operations.

---

(1)	Fair-value of derivative instruments does not include any related accrued interest payable, which is included in accrued expenses on the accompanying consolidated balance sheets. Derivative valuations are classified in Level 2 of the fair-value

---

(2)	Translation to U.S. dollars is based on exchange rates of $1.56 to £1.00 and $1.65 to £1.00 at December 31, 2014 and December 31, 2013, respectively.

(1)	Amount represents payments made to swap counterparties for the effective portion of interest rate swaps that were recognized as an increase to interest expense for the periods presented (the amount was recorded as an increase and corresponding decrease to accumulated other comprehensive loss in the same accounting period).

(2)	Amount represents reclassifications of deferred interest costs from accumulated other comprehensive loss to interest expense related to the Company’s previously settled forward starting swaps.

---

(1)	Fair-values of debt and derivative instruments are classified in Level 2 of the fair-value hierarchy. Fair-value of available-for-sale securities are classified in Level 1 of the fair-value hierarchy.

(2)	The principal balance represents the U.S. dollar amount based on the exchange rate of $1.56 to £1.00 and $1.65 to £1.00 at December 31, 2014 and December 31, 2013, respectively.

(3)	The Company’s derivative instruments are reflected in other assets and in accounts payable, accrued expenses and other liabilities on the accompanying consolidated balance sheets based on their respective balances (see Note 9).

---

(1)

The property is currently under construction in New Haven Connecticut and is expected to be a 510,419 square foot laboratory and office building. The total project investment was estimated to be approximately $191 million at acquisition, comprised of (a) approximately $89 million in cash, assumption of mortgage notes payable and a noncontrolling interest of Winstanley Enterprises LLC and affiliates, which will also continue to provide construction and property management services for the property, and (b) approximately $102 million of estimated remaining construction costs from the date of acquisition. As of April 4, 2014, Winstanley Enterprises, LLC and affiliates retained an approximate 25% noncontrolling interest. On June 3, 2014, Winstanley Enterprises LLC and its affiliates' noncontrolling interest was reduced to approximately 7% as a result of additional investments by the Company. Upon completion of construction and repayment of the related construction loan, the Company expects Winstanley Enterprises LLC and its affiliates' noncontrolling interest in the property to be reduced to approximately 2.5%.

(2)	The property is a 518,940 square foot laboratory and office building in New Haven, Connecticut. The total consideration also included the assumption of $46.3 million of mortgage notes payable and a 7% noncontrolling interest of Winstanley Enterprises LLC, which will also continue to provide property management services for the property.

(3)	The property is currently under construction in Cambridge, United Kingdom and is expected to be a 42,410 square foot laboratory and office building. The total project investment at acquisition was expected to be approximately $22.7 million.

(4)	The property is currently under construction in Winston-Salem, North Carolina and is expected to be a 283,250 square foot laboratory and office building.

(1)	The sales price was equal to the fair-value of the office property received as consideration in the exchange with the independent third party.

---

---

---

---

(1)	The sum of quarterly financial data may vary from the annual data due to rounding.

(1)	The sum of quarterly financial data may vary from the annual data due to rounding.

---

---

---

---

(1)	Includes mortgage notes secured by various properties but excludes unamortized debt premium of $12.9 million.

(2)	The aggregate gross cost of the Company’s rental property for federal income tax purposes approximated $6.7 billion as of December 31, 2014 (unaudited).

(3)	Depreciation of building and improvements is recorded on a straight-line basis over the estimated useful lives ranging from less than one year to 40 years.

(4)	The property or a portion of the property was under active new construction or land bank as of December 31, 2014.

(5)	The property or a portion of the property represents the potential for ground-up development.

(6)	During 2007, the Company acquired a fee simple interest in the land at its Landmark at Eastview property. The balance of $14.2 million was subsequently reclassified from ground lease to land.

---

---

---

---

---

---

---

(1)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 26, 2013.

(2)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 20, 2004.

(3)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2009.

(4)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 22, 2010.

(5)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2013.

---

(6)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 6, 2013.

(7)	Incorporated herein by reference to BioMed Realty Trust, Inc. and BioMed Realty, L.P.’s Registration Statement on Form S-4 (File No. 333-168968), filed with the Securities and Exchange Commission on August 20, 2010.

(8)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2013.

(9)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Registration Statement on Form S-11, as amended (File No. 333-115204), filed with the Securities and Exchange Commission on May 5, 2004.

(10)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2010.

(11)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 30, 2010.

(12)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2011.

(13)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 28, 2012.

(14)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 23, 2014.

(15)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2007.

(16)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 10, 2014.

(17)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2013.

(18)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 30, 2014.

(19)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2010.

(20)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 31, 2012.

(21)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 9, 2012.

(22)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 2, 2015.

(23)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2010.

(24)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 31, 2010.

(25)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2013.

(26)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012.

(27)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 2, 2012.

(28)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 26, 2006.

(29)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s and BioMed Realty, L.P.’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2013.

(30)	Incorporated herein by reference to BioMed Realty Trust, Inc.’s Registration Statement on Form S-3 (File No. 333-143658), filed with the Securities and Exchange Commission on June 11, 2007.

---